Approval for the optimizer smart system. The device which delivers cardiac contractility modulation therapy, is indicated to improve 6-minute hall walk distance, quality of life, and functional status of nyha class iii heart failure patients who remain symptomatic despite guideline directed medical therapy, who are in normal sinus rhythm, are not indicated for cardiac resynchronization therapy, and have a left ventricular ejection fraction ranging from 25% to 45%.
Supplemental Filings
Supplement Number | Date | Supplement Type |
P180036 | | Original Filing |
S015 |
2022-07-22 |
Normal 180 Day Track No User Fee |
S014 | | |
S013 | | |
S012 | | |
S011 |
2021-09-28 |
Real-time Process |
S010 |
2021-09-16 |
Normal 180 Day Track No User Fee |
S009 | | |
S008 |
2021-06-24 |
Normal 180 Day Track |
S007 |
2020-09-09 |
Normal 180 Day Track |
S006 |
2020-06-22 |
Normal 180 Day Track |
S005 |
2020-02-26 |
Normal 180 Day Track |
S004 |
2020-01-09 |
Real-time Process |
S003 |
2019-08-21 |
Normal 180 Day Track |
S002 |
2019-06-21 |
Real-time Process |
S001 |
2019-04-26 |
Real-time Process |
NIH GUDID Devices